A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

This article is protected by copyright. All rights reserved.

Source: Pigment Cell Research - February 17, 2018 Category: Cytology Authors: Janice M. Mehnert, Ann W. Silk, Yu Wen, J. H. Lee, Liesel Dudek, Byeong ‐Seon Jeong, Jiadong Li, Jason M. Schenkel, Evita Sadimin, Michael Kane, Hongxia Lin, Weichung J. Shih, Andrew Zloza, Suzie Chen, James. S. Goydos Tags: Short Communication Source Type: research